1-2 of 2
Rebeca Rodriguez-Veiga
Close
Sort by
Journal Articles

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

Esperanza Martín-Sánchez, Laura Blanco, Peter S. Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesus F. San Miguel, Ana Alfonso, Juan Bergua, Rebeca Rodríguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Bruno Paiva, Aintzane Zabaleta
Journal: Blood Advances
Blood Adv (2024) 8 (15): 3875–3879.
https://doi.org/10.1182/bloodadvances.2024013212
Published: 2024
Includes: Supplemental data
Journal Articles

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

Clinical Trials & Observations
Marina Y. Konopleva, Christoph Röllig, Jamie Cavenagh, Dries Deeren, Larisa Girshova, Jürgen Krauter, Giovanni Martinelli, Pau Montesinos, Jonas A. Schäfer, Oliver Ottmann, Mario Petrini, Arnaud Pigneux, Alessandro Rambaldi, Christian Recher, Rebeca Rodriguez-Veiga, David Taussig, Norbert Vey, Sung-Soo Yoon, Marion Ott, Susanne Muehlbauer, Benjamin M. Beckermann, Olivier Catalani, Magali Genevray, Kirsten Mundt, Candice Jamois, Pierre Fenaux, Andrew H. Wei
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4147–4156.
https://doi.org/10.1182/bloodadvances.2021006303
Published: 2022
Includes: Supplemental data